TDDC dba GI Alliance Research

4 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	NCT ID
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis	Moderately to Severely Active Ulcerative Colitis	Active, not recruiting	Phase 3	2026-10-02	NCT06588855
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease	Moderately to Severely Active Crohns Disease	Recruiting	Phase 3	2026-09-16	NCT06819878
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis	Moderately to Severely Active Ulcerative Colitis	Active, not recruiting	Phase 3	2026-09-14	NCT06589986
A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have	Digestive System Diseases, Eosinophilia, Eosinophilic enteropathy, Hemic and Lymphatic Diseases, Hypersensitivity, Immediate, digestive system disorder, eosinophilic esophagitis, eosinophilic gastroenteritis, esophageal disorder, esophagitis, gastroenteritis, hematologic disorder, immune system disorder, leukocyte disorder	Active, not recruiting	Phase 2	2026-07-01	NCT05831176

Clinical trials